Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
- Co-led by new investor Mission BioCapital and existing investor Novo Holdings, with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital
- Company will now advance danegaptide, a pioneering, first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy (NPDR), into a Phase II clinical trial
- Funding will also be used to mature Breye’s wider pipeline of assets for retinal diseases, including its P2X7 receptor antagonist for intermediate age-related macular degeneration (iAMD)
Copenhagen, Denmark, 29 September 2026 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of an over-subscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital.
